EXCOR儿童心室辅助等待移植的死亡风险:日本注册研究
基于日本EXCOR注册研究,纳入2012年8月至2025年3月间137例接受EXCOR儿童型心室辅助装置作为移植桥接的患者。中位年龄15.4个月,中位体重7.2kg,1年生存率92.9%。植入时体重低于5kg是等待列表死亡的唯一风险因素(p=0.039,HR 2.43,95%CI 1.05-5.68)。
要点
- EXCOR儿童型桥接移植预后良好,1年生存率92.9%。
- 植入时体重<5kg是等待列表死亡的唯一独立风险因素。
- 先天性心脏病与限制性心肌病等待死亡率与扩张型心肌病相当。
核心结论
- 日本EXCOR注册数据显示,EXCOR儿童型作为移植桥接治疗的预后良好。
- 植入时体重低于5kg是等待列表死亡的唯一风险因素。
研究设计与样本
- 回顾性注册研究,纳入2012年8月至2025年3月日本EXCOR注册中接受EXCOR儿童型植入作为移植桥接的患者,共137例。
- 评估早期手术时代、原发诊断、植入年龄、植入体重、双心室辅助、术前ECMO支持及术前机械通气对等待列表死亡率的影响。
主要发现
- 中位植入年龄15.4个月(IQR 7.3-43.2),中位体重7.2kg(IQR 5.5-10.9)。
- 原发诊断:扩张型心肌病100例(72.9%),先天性心脏病20例(14.6%),限制性心肌病8例(5.8%)。
- 70例(51.0%)支持时间超过1年,1年生存率为92.9%。
- 植入时体重低于5kg是等待列表死亡的唯一风险因素(p=0.039,HR 2.43,95%CI 1.05-5.68)。
- 先天性心脏病和限制性心肌病患者的等待列表死亡率与扩张型心肌病患者相当(p=0.390,HR 1.29,95%CI 0.72-2.33)。
临床怎么用
- 对于体重低于5kg的患儿,植入EXCOR儿童型作为移植桥接时需警惕等待列表死亡风险升高。
- 先天性心脏病和限制性心肌病患儿接受EXCOR儿童型桥接移植的等待死亡率与扩张型心肌病相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To reveal the prognostic outcomes of ventricular assist device (VAD) therapy with EXCOR paediatric® in Japan. METHODS: Patients who underwent EXCOR paediatric implantation as a bridging therapy to transplant between August 2012 and March 2025 were enrolled. The following risk factors were evaluated for their potential to influence waitlist mortality: early surgical era, primary diagnosis, age at implantation, weight at implantation, biventricular VAD support, preoperative extracorporeal membrane oxygenation support, and preoperative mechanical ventilator support. RESULTS: The total number of 137 patients was identified. The median age and weight at the time of implantation were 15.4 months (interquartile range: 7.3-43.2) and 7.2 kg (5.5-10.9), respectively. The primary diagnosis was dilated cardiomyopathy in 100 patients (72.9%), congenital heart disease in 20 patients (14.6%), and restrictive cardiomyopathy in 8 patients (5.8%). Of those, 70 (51.0%) were supported for a period exceeding one year, and the one-year survival rate was found to be 92.9%. A weight of less than 5 kg at the time of Excor implantation was identified as the sole risk factor for mortality on the waitlist (p = 0.039, Hazard ratio: 2.43, 95% confidence interval: 1.05-5.68). In particular, the mortality rate of patients on the waiting list for congenital heart disease and restrictive cardiomyopathy was comparable to that of patients with dilated cardiomyopathy (p = 0.390, hazard ratio: 1.29, 95% confidence interval: 0.72-2.33). CONCLUSIONS: An analysis of JEXCOR registry data demonstrated that the prognostic outcome of bridge-to-transplant therapy with Excor paediatric was favorable in Japan.
引用
- Hoashi T, Asase M, Sakaguchi H, et al. Waitlist mortality in children with EXCOR support: An analysis of the Japan Excor registry. Eur J Cardiothorac Surg. 2026. PMID: 41555485. doi:10.1093/ejcts/ezag033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。